Harnessing SARS-CoV-2-specific CD8⁺ T cells to kill target tumor cells for cancer immunotherapy.

ABSTRACT:

SUBMITTER: Jung K 

PROVIDER: S-EPMC10794008 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature